In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vectura Group PLC

www.vectura.com

Latest From Vectura Group PLC

Vectura Prevails In US Litigation Over GSK’s Ellipta

Vectura has won an award of almost $90m after convincing a Delaware jury that GSK’s Ellipta respiratory range infringed one of its US patents. The firm currently has a development deal with Hikma for generic versions.

Legal Issues Generic Drugs

Rovi and Recordati Deemed Top Picks By Analyst

The team at Jefferies believe that the Spanish and Italian firms, as well as Hikma, are looking like good bets for the year ahead.

Market Intelligence Europe

Vectura Breathes Easy As It Enters Eventful 2019

With a steady stream of royalties coming in from Flutiform and Ultibro and a decent pipeline of innovative respiratory drugs and generics, Vectura has presented a promising update for the year ahead.

Sales & Earnings Respiratory

Severe Asthma Proves Too Much Of A Challenge For Vectura

An ambitious trial of a budesonide-based drug/device combo for uncontrolled asthma has failed, but Vectura is upbeat as it switches resources to a potential pediatric asthma treatment.

Respiratory Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register